PhEED, a new RCT for post ischemic or hemorrhagic stoke patients with dysphagia has started enrollment in the US and Europe

May 2018

Pharyngeal Electrical Stimulation Evaluation for Dysphagia after Stroke (PhEED) is a prospective multi-centre randomised controlled single-blinded trial with Non-Significant Risk status granted by FDA.

If you are a healthcare professional working in an acute rehab center and are interested in being part of PhEED in US, please contact Nadine Juran at nadine.juran@phagenesis.com.

For more information click here.

Posted in General updates | Comments Off on PhEED, a new RCT for post ischemic or hemorrhagic stoke patients with dysphagia has started enrollment in the US and Europe

First PHAST-TRAC results were presented at ISC 2018

January 2018

The first results of Pharyngeal Electrical Stimulation for Early Decannulation in Tracheotomised Stroke Patients with Dysphagia (PHAST-TRAC): A Randomised, Single-blind, Pivotal, Superiority Trial were presented by Professor Philip M Bath, University of Nottingham, Nottingham, United Kingdom at International Stroke Conference, Los Angeles, 24-26 January 2018 read more.

Medscape also featured the results of the Phagenesis’ PHAST-TRAC study, based on Prof. Bath ’s presentation on Friday. This is a major achievement for Phagenesis Ltd promoting Phagenyx® internationally read more.

Posted in General updates | Comments Off on First PHAST-TRAC results were presented at ISC 2018

Phagenesis has successfully reached the first of two milestones in its staged acquisition agreement with Nestlé Health Science

October 2017

Phagenesis

Manchester, 4 October 2017 – Phagenesis announced today that by completing a key clinical study in Europe it has reached the first milestone in its staged acquisition agreement with Nestlé Health Science (NHSc). Under the terms of the agreement, Nestlé Health Science has acquired an additional stake in Phagenesis.

Reinhard Krickl, CEO of Phagenesis, said: “We are very happy to have successfully closed a key clinical study demonstrating the clinical benefit of Phagenyx®* for the treatment of post-stroke dysphagia amongst tracheostomized patients. We are looking forward to having the study results published early 2018.” 

Phagenesis is a medical device company that has developed a new treatment for dysphagia, the inability to swallow safely. Dysphagia is a condition with high prevalence as well as high clinical and health economic burden. It is a debilitating condition, which frequently leads to life-threatening complications, including aspiration pneumonia, malnutrition and dehydration. Furthermore, patients with dysphagia experience a dramatic reduction in Quality-of-Life1.

Oern Stuge, Chairman of Phagenesis, stated: “Nestlé Health Science’s increasing stake in Phagenesis will continue to foster a strong collaboration between Phagenesis and NHSc, allowing Phagenesis to accelerate its clinical programs demonstrating the benefit of Phagenyx® for this significant unmet medical need.” 

Gunnar Weikert, Director of Phagenesis and Founder of Inventages Venture Capital commented: “As a long-term investor in Phagenesis we are pleased about this significant achievement and look forward to working more closely with NHSc.

Currently, the management of neurogenic dysphagia is complex. Available options can improve the status and the symptoms, but few are treating the cause. Phagenesis has developed Phagenyx®, a novel medical device designed to restore the neurological control of swallowing. Phagenyx® is based on ground-breaking research that establishes a mechanism of action of delivering Pharyngeal Electrical Stimulation (PES) to treat the neurological cause of dysphagia.

_________                                                                                                                                            * Phagenyx® system is CE marked and is available for sale only in the European Economic Area and Switzerland.

Glossary of terms 

Dysphagia [dis-fa´jah] = difficulty in swallowing, also known as aphagia.

Neurogenic dysphagia = neurological oropharyngeal dysphagia is a difficulty in swallowing, caused by several neurological conditions such as stroke.

Bibliography

1 Marik P et al. Aspiration Pneumonia and Dysphagia in the Elderly. Chest 2003.124;328-336.

For more information, please contact:                                                                       

Irina Manoliu, MD, MSc, CMM Global Marketing Manager

PHAGENESIS LIMITED 

Address: Unit 18, Enterprise House, Manchester Science Park, Manchester, M15 6SE

Tel: +44 (0) 161 820 9562; Mobile: +44 (0) 7508 265 151; Fax: +44 (0) 161 820 4529

Website: www.phagenesis.com

Forward-Looking Statements

This news release may contain forward-looking statements based on current assumptions and forecasts made by Nestlé Health Science and Phagenesis management. Various known and unknown risks, uncertainties and other factors could lead to differences between the actual, future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Nestlé Health Science’ and Phagenesis’ public reports. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

 

Posted in General updates, news | Comments Off on Phagenesis has successfully reached the first of two milestones in its staged acquisition agreement with Nestlé Health Science

Phagenyx® Next Generation Catheter is launched at 7th ESSD Congress and World Dysphagia Summit, 18-23 September 2017

September 2017

Barcelona, Spain – 21st September 2017 – Phagenesis announced today the official launch of the Phagenyx® Next Generation catheter, the result of company’s engagement to continuous innovation and product improvement.

The participants at 7th ESSD Congress and World Dysphagia Summit, Barcelona, 18-23 September 2017 will have the chance to see and test the new product at Phagenesis stand. The Phagenyx® Next Generation catheter allows an optimal and customised treatment, as well as safe feeding for every patient.

Phagenyx® is an evidence based innovative treatment targeting the cause of neurogenic dysphagia. It uses Pharyngeal Electrical Stimulation (PES) to restore neurological control of swallowing, thus reducing the risk of complications and associated costs and improving patient’s outcomes.

The Phagenyx® system delivers a calibrated electrical signal to the back of the throat (oropharynx) for 10 minutes a day for three consecutive days. Randomised controlled trials have shown that this protocol leads to a clinically and statistically significant improvement in swallowing function in the majority of patients with neurogenic dysphagia.

The treatment is based on over 20 years of research and development led by Professor Shaheen Hamdy at the University of Manchester, UK.

Posted in General updates | Comments Off on Phagenyx® Next Generation Catheter is launched at 7th ESSD Congress and World Dysphagia Summit, 18-23 September 2017

Phagenyx® Next Generation Catheter obtains CE Mark

July 2017

Manchester, UK – 21st July 2017 – Phagenesis Ltd, an important leader in the treatment of dysphagia, announced today that Phagenyx® Next Generation catheter got CE Mark for neurogenic dysphagia.

Dysphagia (the inability to swallow safely) is a condition with important prevalence as well as high clinical and health economic burden. Dysphagia occurs in 29-55% of stroke patients1, while 15 million people worldwide suffer a stroke2 every year and is common also in many other diseases.

Dysphagia is a debilitating condition that frequently leads to life-threatening complications, including aspiration pneumonia, malnutrition, dehydration and the surgical implantation of a PEG tube to allow a patient to be fed indefinitely through the abdomen wall. Furthermore, patients with dysphagia experience a dramatic reduction in Quality-of-Life3.

Phagenesis remains committed to transforming the lives of people with dysphagia by launching in 2017 Phagenyx® Next Generation catheter. It is the result of company’s engagement to continuous innovation and product improvement. The dysphagia treatment will be easier with the Phagenyx® Next Generation catheter, which allows an optimal and customized treatment, as well as safe feeding for every patient.

Phagenyx® provides a unique innovative treatment for neurogenic dysphagia that uses Pharyngeal Electrical Stimulation (PES) to restore neurological control and in turn improve the swallow function. Phagenyx® is designed to treat the cause of dysphagia, thereby reducing the risk of complications and associated costs and improving outcomes.

The Phagenyx® treatment system delivers a calibrated electrical signal to the back of the throat (oropharynx) for 10 minutes a day for three consecutive days. This protocol has shown to lead to a clinically and statistically significant improvement in swallowing function in a majority of dysphagia patients.

The treatment is based on over 20 years of research and development led by Professor Shaheen Hamdy at the University of Manchester, UK.

Bibliography

1. Martino R., Foley N., Bhogalet S. et al. Dysphagia after stroke: incidence, diagnosis, and pulmonary complications. Stroke 2005; 36, 2756–2763.

2.http://www.world-heart-federation.org/cardiovascular-health/stroke/

3.Marik P. et al. Aspiration Pneumonia and Dysphagia in the Elderly. Chest 2003.124;328-336.

 

 

Posted in General updates | Comments Off on Phagenyx® Next Generation Catheter obtains CE Mark